Shionogi announced today that it has obtained manufacturing and marketing approval in Japan for their digital therapeutic app “ENDEAVORRIDE®.” Based on VT subsidiary Akili’s Endeavor product line, Shionogi’s ENDEAVORRIDE is a digital therapeutic app designed for pediatric patients in Japan with attention-deficit/hyperactivity disorder (ADHD).
The result of a multi-year collaboration, Akili is thrilled that Shionogi is one step closer to launching this new digital therapeutic treatment in Japan to help individuals with ADHD and their families.
Congratulations to our partner Shionogi for this important achievement!
Comments